Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Legal Initiatives Necessary to Ensure Stable Drug Supplies: MHLW Official
March 28, 2022
-
ORGANIZATION FPMAJ Begins Survey on Risk of Mineral Resource Shortages amid Ukraine War
March 28, 2022
-
REGULATORY Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
March 25, 2022
-
REGULATORY Japan Panel Agrees to Prep for Fourth Shot, but Wants Cautious Approach; Free Booster OK’ed for Ages 12-17
March 25, 2022
-
REGULATORY Enhertu Braced for Price Cuts as Chuikyo OKs CEA Results; Evrysdi Not Subject to Scheme
March 24, 2022
-
REGULATORY Pfizer COVID Booster OK’ed for Ages 12-17, Comirnaty Label Revised
March 24, 2022
-
REGULATORY Kyowa Pharma to Face Biz Suspension Order over Manufacturing Flaws
March 23, 2022
-
REGULATORY AMED’s SCARDA Boots Up as Command Tower for Vaccine Development
March 23, 2022
-
ORGANIZATION Number of MSLs Tops 1,000 in FY2021, Up 50% in 2 Years; Lack of Talent an Obstacle to Further Growth: JAPhMed
March 22, 2022
-
BUSINESS Sanofi Files PD-1 Drug Cemiplimab for Cervical Cancer in Japan
March 22, 2022
-
BUSINESS Generic Makers, PMDA Exploring GMP Inspection Methods for Overseas Sites; Onsite Checks Not Possible for 2 Years
March 18, 2022
-
REGULATORY MHLW Panel to Discuss Pfizer COVID Booster for Ages 12-17
March 18, 2022
-
BUSINESS Aduhelm Deal Revised, Eisai Poised to Sharpen Focus on Lecanemab: CEO
March 17, 2022
-
COMMENTARY Drug Makers Guard against Price Adjustment Rate, Off-Year Revision Debates: Jiho Poll
March 16, 2022
-
BUSINESS Biogen/Eisai Alzheimer’s Pact Amended to Switch Aducanumab Collab to Royalty Scheme
March 16, 2022
-
ORGANIZATION API Import Costs from Europe Surging amid Russian Airspace Closures
March 15, 2022
-
ORGANIZATION List of 180 Needed Drugs Compiled in Europe-Led Drive to Support Ukraine
March 14, 2022
-
BUSINESS Moderna Accelerating Bivalent Vaccine Development for 4th COVID Shot: Japan Chief
March 14, 2022
-
BUSINESS Fujifilm Drops Avigan’s Japan PIII Trial for COVID-19
March 14, 2022
-
BUSINESS Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally
March 11, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…